Tumor genome sequencing available

Tumor genome sequencing is now available at Kettering Health Network for patients with an advanced form of the disease as part of a national, industry-sponsored study by Strata Oncology, a precision oncology company.

Kettering Health Network is one of only eight sites in the country and the only one in Ohio to offer this unique tumor profiling and clinical trial to advanced cancer patients.

The trial is open to patients who are receiving care at Kettering Medical Center, Soin Medical Center or Fort Hamilton Hospital for advanced-stage or rare cancers, including all pancreatic and glioblastoma cancers, and latestage solid tumors, lymphoma and lung cancers. Patients who participate in the Strata trial receive no-cost tumor sequencing and, in some cases, access to investigational therapies matched to the genomic profile of their tumor.

Enrollment began in Fall 2017 and on average, Kettering Health Network is enrolling 50 patients per month in the Strata trial. Strata screens for 90 genomic mutations, and within two weeks, the oncologist receives a genomic profile that can drive treatment from the outset. Strata also provides a list of studies for which the patient may be eligible, and directs patients to additional resources that may provide access to studies elsewhere.

For more information, visit www.ketteringhealth.org.